Indication
Synergy for Citrobacter meningitis
Synergy for *Citrobacter* meningitis refers to the pharmacodynamic objective of using combination antimicrobial therapy to produce an enhanced, supra-additive bactericidal effect against central nervous system infections caused by *Citrobacter* species (predominantly *Citrobacter koseri* or *Citrobacter freundii*). Read more about Synergy for Citrobacter meningitis
12 drugs 11 manufacturers
Drugs that treat it
Common Synergy for Citrobacter meningitis therapies.
GENTAMICIN IN NACL (ISO-OSM) (gentamicin sulfate in sodium chloride, iso-osmotic)
GENTAMICIN SULFATE (gentamicin sulfate/PF)
GENTAMICIN SULFATE (gentamicin sulfate/PF)
GENTAMICIN SULFATE IN NS (gentamicin sulfate in sodium chloride, iso-osmotic)
GENTAMICIN SULFATE (gentamicin sulfate/PF)
GENTAMICIN SULFATE
GENTAMICIN SULFATE (gentamicin sulfate/PF)
GENTAMICIN SULFATE (gentamicin sulfate/PF)
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonSynergy for *Citrobacter* meningitis refers to the pharmacodynamic objective of using combination antimicrobial therapy to produce an enhanced, supra-additive bactericidal effect against central nervous system infections caused by *Citrobacter* species (predominantly *Citrobacter koseri* or *Citrobacter freundii*).
This clinical state involves severe inflammation of the meninges and cerebral tissue, most characteristically occurring in neonates and young infants, though occasionally affecting immunocompromised or post-neurosurgical adults.
It is pathologically distinguished by invasive bacterial vasculitis, extensive tissue necrosis, and a disproportionately high incidence of ventriculitis and liquefactive brain abscess formation.
Because *Citrobacter* isolates frequently harbor chromosomal AmpC beta-lactamases or plasmid-mediated extended-spectrum beta-lactamases that confer multidrug resistance, synergistic regimens are utilized to accelerate cerebrospinal fluid sterilization and mitigate rapid parenchymal destruction.
- fmhr.net
Synergy for *Citrobacter* meningitis refers to the pharmacodynamic objective of using combination antimicrobial therapy to produce an enhanced, supra-additive bactericidal effect against central nervous system infections caused by *Citrobacter* species (predominantly *Citrobacter koseri* or *Citrobacter freundii*) Because *Citrobacter* isolates frequently harbor chromosomal AmpC beta-lactamases or plasmid-mediated extended-spectrum beta-lactamases that confer multidrug resistance, synergistic re...
- einsteinmed.edu
Synergy for *Citrobacter* meningitis refers to the pharmacodynamic objective of using combination antimicrobial therapy to produce an enhanced, supra-additive bactericidal effect against central nervous system infections caused by *Citrobacter* species (predominantly *Citrobacter koseri* or *Citrobacter freundii*)
- plos.org
Synergy for *Citrobacter* meningitis refers to the pharmacodynamic objective of using combination antimicrobial therapy to produce an enhanced, supra-additive bactericidal effect against central nervous system infections caused by *Citrobacter* species (predominantly *Citrobacter koseri* or *Citrobacter freundii*) Because *Citrobacter* isolates frequently harbor chromosomal AmpC beta-lactamases or plasmid-mediated extended-spectrum beta-lactamases that confer multidrug resistance, synergistic re...
- oup.com
Synergy for *Citrobacter* meningitis refers to the pharmacodynamic objective of using combination antimicrobial therapy to produce an enhanced, supra-additive bactericidal effect against central nervous system infections caused by *Citrobacter* species (predominantly *Citrobacter koseri* or *Citrobacter freundii*) This clinical state involves severe inflammation of the meninges and cerebral tissue, most characteristically occurring in neonates and young infants, though occasionally affecting imm...
- omjournal.org
This clinical state involves severe inflammation of the meninges and cerebral tissue, most characteristically occurring in neonates and young infants, though occasionally affecting immunocompromised or post-neurosurgical adults Because *Citrobacter* isolates frequently harbor chromosomal AmpC beta-lactamases or plasmid-mediated extended-spectrum beta-lactamases that confer multidrug resistance, synergistic regimens are utilized to accelerate cerebrospinal fluid sterilization and mitigate rapid p...
- nih.gov
This clinical state involves severe inflammation of the meninges and cerebral tissue, most characteristically occurring in neonates and young infants, though occasionally affecting immunocompromised or post-neurosurgical adults
- ispub.com
It is pathologically distinguished by invasive bacterial vasculitis, extensive tissue necrosis, and a disproportionately high incidence of ventriculitis and liquefactive brain abscess formation
- ajnr.org
It is pathologically distinguished by invasive bacterial vasculitis, extensive tissue necrosis, and a disproportionately high incidence of ventriculitis and liquefactive brain abscess formation
- asm.org
It is pathologically distinguished by invasive bacterial vasculitis, extensive tissue necrosis, and a disproportionately high incidence of ventriculitis and liquefactive brain abscess formation
Personalize your experience
Follow Synergy for Citrobacter meningitis and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.